Form 13-F position report

ACORDA THERAPEUTICS INC COM NE

Reported by Bruce & Co Inc

ACOR CUSIP 00484MAB2 Manager CIK 0001358331

Reported 5,000,000 shares, up 4,750,000 (1900.0%) from the prior quarter.

Reported value 0.7%; share count 1900.0% vs. the prior quarter.

Added
% of reported 13F value 0.92% This manager · Q2 2023
Shares 5,000,000 Quarter-end amount reported
Reported value $3,272,500 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 4075000
2022-03-31 3750000
2022-06-30 3700000
2022-09-30 3700000
2022-12-31 3750000
2023-03-31 3250455
2023-06-30 3272500
2023-09-30 2925000
2023-12-31 2437500
2024-03-31 2850000
2024-06-30 3500000
2024-09-30 200000
2024-12-31 200000
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ACORDA THERAPEUTICS INC COM NE held by Bruce & Co Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -5,000,000 (-100.0%) 0 $0 2025-05-14
Q4 2024 Unchanged 5,000,000 0 (0.0%) 0.06% $200,000 2025-02-11
Q3 2024 Unchanged 5,000,000 0 (0.0%) 0.06% $200,000 2024-11-14
Q2 2024 Unchanged 5,000,000 0 (0.0%) 1.15% $3,500,000 2024-08-09
Q1 2024 Unchanged 5,000,000 0 (0.0%) 0.95% $2,850,000 2024-05-13
Q4 2023 Unchanged 5,000,000 0 (0.0%) 0.85% $2,437,500 2024-02-12
Q3 2023 Unchanged 5,000,000 0 (0.0%) 1.0% $2,925,000 2023-11-13
Q2 2023 Added 5,000,000* +4,750,000 (1900.0%) 0.92% $3,272,500 2023-08-08
Q1 2023 Unchanged 5,000,000 0 (0.0%) 0.89% $3,250,455 2023-05-12
Q4 2022 Unchanged 5,000,000 0 (0.0%) 0.97% $3,750,000 2023-02-15
Q3 2022 Unchanged 5,000,000 0 (0.0%) 1.02% $3,700,000 2022-11-15
Q2 2022 Unchanged 5,000,000 0 (0.0%) 0.87% $3,700,000 2022-08-09
Q1 2022 Unchanged 5,000,000 0 (0.0%) 0.77% $3,750,000 2022-05-11
Q4 2021 Unchanged 5,000,000 0 (0.0%) 0.81% $4,075,000 2022-02-16
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1 manager reported ACORDA THERAPEUTICS INC COM NE for Q2 2023.

Managers reporting ACORDA THERAPEUTICS INC COM NE in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bruce & Co Inc This report Added 5,000,000 +4,750,000 0.92% $3,272,500 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 08, 2023
Filing type
13F-HR
Position type
Cv 6.0%

Voting authority reported

Sole
5,000,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.